Brent A Hanks
Overview
Explore the profile of Brent A Hanks including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
1659
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Atkins M, Curiel-Lewandrowski C, Fisher D, Swetter S, Tsao H, Aguirre-Ghiso J, et al.
Clin Cancer Res
. 2021 Jan;
27(10):2678-2697.
PMID: 33414132
Five years ago, the Melanoma Research Foundation (MRF) conducted an assessment of the challenges and opportunities facing the melanoma research community and patients with melanoma. Since then, remarkable progress has...
22.
Hu-Lieskovan S, Bhaumik S, Dhodapkar K, Grivel J, Gupta S, Hanks B, et al.
J Immunother Cancer
. 2020 Dec;
8(2).
PMID: 33268350
Since the publication of the Society for Immunotherapy of Cancer's (SITC) original cancer immunotherapy biomarkers resource document, there have been remarkable breakthroughs in cancer immunotherapy, in particular the development and...
23.
Strickler J, Hanks B, Khasraw M
Clin Cancer Res
. 2020 Nov;
27(5):1236-1241.
PMID: 33199494
Immune checkpoint inhibitors, including antibodies that block programmed cell death protein-1 (PD-1) and PD-L1, have transformed the management of many cancers. However, the majority of patients have primary or acquired...
24.
Salama A, Palta M, Rushing C, Selim M, Linney K, Czito B, et al.
Clin Cancer Res
. 2020 Nov;
27(5):1287-1295.
PMID: 33172894
Purpose: In this prospective trial, we sought to assess the feasibility of concurrent administration of ipilimumab and radiation as adjuvant, neoadjuvant, or definitive therapy in patients with regionally advanced melanoma....
25.
Ravichandran S, Nath N, Jones D, Li G, Suresh V, Brys A, et al.
Surg Oncol
. 2020 Nov;
35:533-539.
PMID: 33161362
Background: This study evaluates the utility of whole-body PET-CT for the initial staging and subsequent surveillance imaging of patients with completely resected stage II and stage III melanoma. Methods: A...
26.
Hu J, Ravichandran S, Rushing C, Beasley G, Hanks B, Jung S, et al.
Anticancer Res
. 2020 Sep;
40(9):5245-5254.
PMID: 32878813
Background/aim: To determine whether BMI and sarcopenia were related to treatment-limiting toxicity or efficacy of pembrolizumab treatment in melanoma patients. Patients And Methods: Medical records for melanoma patients undergoing pembrolizumab...
27.
Beasley G, Therien A, Holl E, Al-Rohil R, Selim M, Farrow N, et al.
Cancer Immunol Immunother
. 2020 Aug;
70(2):475-483.
PMID: 32814992
Background: In melanoma patients, microscopic tumor in the sentinel lymph-node biopsy (SLN) increases the risk of distant metastases, but the transition from tumor in the SLN to metastatic disease remains...
28.
Plebanek M, Sturdivant M, DeVito N, Hanks B
Int Immunol
. 2020 May;
32(7):485-491.
PMID: 32449776
The dendritic cell (DC) is recognized as a vital mediator of anti-tumor immunity. More recent studies have also demonstrated the important role of DCs in the generation of effective responses...
29.
Theivanthiran B, Evans K, DeVito N, Plebanek M, Sturdivant M, Wachsmuth L, et al.
J Clin Invest
. 2020 Feb;
130(5):2570-2586.
PMID: 32017708
An in-depth understanding of immune escape mechanisms in cancer is likely to lead to innovative advances in immunotherapeutic strategies. However, much remains unknown regarding these mechanisms and how they impact...
30.
DeVito N, Plebanek M, Theivanthiran B, Hanks B
Front Immunol
. 2020 Jan;
10:2876.
PMID: 31921140
The vast majority of cancer-related deaths are due to metastasis, a process that requires evasion of the host immune system. In addition, a significant percentage of cancer patients do not...